Merestinib, also known as LY2801653, is a n orally available, small molecule inhibitor of the proto-oncogene c-Met (mesenchymal-epithelial transition, also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono- and combination therapy in a broad range of cancers.
Related Products:
Capmatinib; MK-8033; SGX-523; MDK-0264; Tepotinib; NPS-1034; WYE-125132; PHA-665752; SCR-1481B1; SU11606